Cerebrolysin
CognitivePeptide hydrolysate / nootropic researchExperimental
Porcine brain-derived peptide hydrolysate used in some countries for stroke and dementia. Not FDA-approved in the US.
For research use only.
Key Facts
- CAS
- 12656-49-6
- Molecular Weight (MW)
- Mixture of low-MW peptides
- Half-life
- Mixture; component PK not a single value
- Unit
- mg
- Administration Route
- Intramuscular
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- Neuronal survival pathwaysNeurotrophic signaling
Overview
Porcine brain-derived peptide hydrolysate used in some countries for stroke and dementia. Not FDA-approved in the US.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- 2–4 weeks typical in regional protocols
- Administration Route
- Intramuscular
- Reconstitution Guide
- —
Science
Mechanism of Action
Mixture of low-molecular-weight neuropeptides claimed to mimic neurotrophic-factor activity (BDNF/GDNF-like effects) and support neuronal survival after ischemia in clinical and preclinical literature.
Targets
Neuronal survival pathwaysNeurotrophic signaling
Studies
- Cerebrolysin in acute ischemic stroke— Journal/year not available
Benefits
Stroke/dementia research literatureNeurotrophic mixture
Potential Side Effects
- Injection reactions
- Agitation
- Headache
- Rare hypersensitivity
References
- PMID 21952694External link · Year —